This site is intended for healthcare professionals

FDA grants accelerated approval for Xpovio to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Karyopharm Therapeutics.

Read time: 1 mins
Last updated:25th Jun 2020
Published:25th Jun 2020
Condition: Diffuse Large B Cell Lymphoma
Type: drug
Register free for full access to